Potential Benefit With Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis.
Potential Benefit With Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis.
复制标题
DOI:
10.1016/j.cgh.2020.09.035
复制
发表时间:
2021-08
期刊:
影响因子:
--
通讯作者:
Shin A
中科院分区:
文献类型:
--
作者:
Billings W;Mathur K;Craven HJ;Xu H;Shin A
Patients with irritable bowel syndrome (IBS) may pursue complementary and alternative medicine (CAM). We conducted a comprehensive systematic review and meta-analysis examining efficacy of CAM vs. placebo or sham in adults with IBS. Publication databases were searched for randomized controlled trials of CAM therapies (herbal therapy, dietary supplements, mind-body based, body-based, and energy-healing) in adults with IBS. Data were extracted to obtain pooled estimates of mean improvement in abdominal pain (standardized mean difference [SMD]) and relative risk (RR) of overall response using random effects models. Sensitivity and subgroup analyses along with quality assessments were completed. Among 2825 articles identified, 66 were included. Herbal therapy (SMD=0.47, 95% CI: 0.20 to 0.75, I2=82%) demonstrated significant benefit over placebo for abdominal pain (low confidence in estimates). Benefit with mind-body based therapy for abdominal pain was of borderline significance (SMD=0.29, 95% CI: −0.01 to 0.59, I2=78%). Herbal therapy (RR=1.57, 95% CI: 1.31 to 1.88, I2=77%), dietary supplements (RR=1.95, 95% CI: 1.02 to 3.73, I2=75%), and mind-body based therapy (RR=1.67, 95% CI: 1.13 to 2.49, I2=63%) showed benefit for overall response compared to placebo (low confidence in estimates). Body-based and energy healing therapies demonstrated no significant benefit over placebo or sham for abdominal pain or overall response. CAM therapies such as herbal or dietary supplements and mind-body based approaches may be beneficial for abdominal pain and overall response in IBS. However, overall quality of evidence is low. Rigorous, high quality clinical trials are warranted to investigate CAM in IBS.
登录
查看更多内容
影响因子:
29.4
作者:
Drossman, DA;Toner, BB;Bangdiwala, SI
通讯作者:
Bangdiwala, SI
DOI:
10.1038/ajg.2011.184
发表时间:
2011-09
期刊:
The American journal of gastroenterology
影响因子:
--
作者:
Gaylord SA;Palsson OS;Garland EL;Faurot KR;Coble RS;Mann JD;Frey W;Leniek K;Whitehead WE
通讯作者:
Whitehead WE
影响因子:
12.6
作者:
Fan, Heng;Zheng, Liang;Xiao, Jun
通讯作者:
Xiao, Jun
影响因子:
7.2
作者:
Chen, Chunqiu;Tao, Chunhua;Fichna, Jakub
通讯作者:
Fichna, Jakub
影响因子:
12.6
作者:
Bensoussan, Alan;Kellow, John E.;Boyce, Philip
通讯作者:
Boyce, Philip